Caption Management’s Ocular Therapeutix OCUL Stock Holding History

Caption Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$391K	Sell	39,800 -342,959	-90%	-$3.11M	﹤0.01%	1375
2026 Q1	$3.24M	Buy	+382,759	New	+$3.65M	0.02%	664
2024 Q4	–	Sell	-22,900	Closed	-$199K	–	1721
2024 Q3	$199K	Hold	22,900	–	–	﹤0.01%	1066
2024 Q2	$157K	Buy	+22,900	New	+$141K	﹤0.01%	985
2023 Q1	–	Sell	-25,000	Closed	-$70.3K	–	1409
2022 Q4	$70.3K	Buy	+25,000	New	+$82.8K	﹤0.01%	1154
2020 Q1	–	Sell	-32,800	Closed	-$162K	–	1005
2019 Q4	$130K	Sell	32,800 -7,200	-18%	-$25K	﹤0.01%	744
2019 Q3	$122K	Buy	+40,000	New	+$179K	0.01%	629

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caption Management's OCUL Position: Q2 2026 in Review

Caption Management reduced its Ocular Therapeutix (OCUL) stake by 90% in Q2 2026, selling an estimated $3.11M and leaving 39,800 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Caption Management first reported a position in OCUL in Q3 2019 and has held it in 7 quarters since. The position peaked at $3.24M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Caption Management held 39,800 shares of Ocular Therapeutix worth $391K as of Q2 2026.
Caption Management sold 342,959 Ocular Therapeutix shares in Q2 2026, an estimated $3.11M.
Ocular Therapeutix made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1375 holding.
Caption Management first reported a position in Ocular Therapeutix in Q3 2019 and has held it in 7 quarters since.
Caption Management's Ocular Therapeutix position peaked at $3.24M in Q1 2026.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.